ARCT-2138 (LUNAR-FLU) Phase 1 topline immunogenicity and safety data, anticipated in Q3 ARCT-810 (LUNAR-OTC) Phase 2 and ARCT-032 (LUNAR-CF) Phase 1b interim data and update to be provided on July 1 ...
The article provides an investment overview of Arcutus, offering insights and analysis, and ways of thinking about the investment opportunity. Arcutus is an mRNA specialist developer with no approved ...
Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to forthcoming clinical data for both the ARCT-032 cystic fibrosis program and the ...
Arcturus, or XBB.1.16, is a new Omicron subvariant that is being monitored by the World Health Organization. The new subvariant is behind a recent COVID-19 surge in India and has been found in the U.S ...
New Covid strain XBB.1.18, nicknamed arcturus, is quickly spreading across the U.S., but experts are warning that pink eye and high fever, two symptoms of the new variant, are particularly present ...
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of ...
“Moderna lost its IPR against the ‘069 patent directed to Arbutus’s LNP delivery technology. That ruling is currently on appeal before the Federal Circuit and Moderna has nonetheless indicated that it ...
University of Westminster provides funding as a member of The Conversation UK. It’s important to note that only a small portion of COVID infections undergo genetic sequencing, so it’s likely there are ...
Q1 2025 Management View Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to forthcoming clinical data for both the ARCT-032 cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results